Harnessing NK cells in cancer therapies / E. Vivier.

Format:

Video

Author/Creator:

Vivier, E., author.

Language:

English

Subjects (All):

Immunity, Innate.

Immunoglobulins.

Physical Description:

1 streaming video file (30 min., 58 sec.) : color, sound

Place of Publication:

London : Henry Stewart Talks Ltd, 2025.

System Details:

video file

Contents:

Introduction

Bringing NK cells to the clinic

Why?

Harnessing innate immunity

The cancer innate immunity cycle

Innate lymphoid cells (ILCs)

The 10 hallmarks of NK cell tumor immunity

What?

What are NK cells?

Subgroups of NK cell subsets

NK subset characterization

NK subset response to cytokines

Putative transcriptional trajectories

NK cell ontogeny

Distribution of NK cell subsets in tissues

Distribution of NK cell subsets in cancer

How?

NK cell therapies: Modalities 1

ANKET: A fit-for-all platform

Trispecific NK cell engager

Trispecific to tetraspecific ANKET

Rationale for including IL-2v

Efficacy of IPH6501 surrogate

Comparing NK engagers to T cell engagers

Mechanisms of ANKET anti-tumor efficacy

ANKET induces NK cell homing

Further mechanisms of ANKET efficacy

In vivo activity of CD20-NKCE-IL2v

ANKET boost NK cell immunity

Tumor Ag-agnostic NK cell immunity

An add-on of NK cell anti-tumor immunity

NK vs. T cell engagers

New immune cell engagers

NK cell therapies: Modalities 2

Monalizumab

Monalizumab study results

Acknowledgements

Disclosures.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved August 14, 2025, from https://doi.org/10.69645/BOKW6993.